Spots Global Cancer Trial Database for Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

Official Title: KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma

Study ID: NCT00478062

Conditions

Lymphoma

Interventions

Hodgkin's antigens-GM-CSF-expressing cell vaccine

adjuvant therapy

Study Description

Brief Summary: RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy works in treating patients who have received first-line therapy for Hodgkin's lymphoma.

Detailed Description: OBJECTIVES: * Determine immunologic responses in patients who have completed first-line therapy for Hodgkin's lymphoma treated with Hodgkin's antigens-GM-CSF-expressing cell vaccine. * Determine the durability of these immunologic responses in these patients. * Determine the utility of an Epstein-Barr virus reporter system for monitoring cellular vaccine responses. * Determine the safety and tolerability of this vaccine in these patients. OUTLINE: Beginning 4-6 months after last chemotherapy, patients receive Hodgkin's antigens-GM-CSF-expressing cell vaccine on day 1. Treatment repeats every 3 weeks for up to 4 courses. Immunologic responses are serially monitored along with disease status. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.